Ambio Life Sciences Launches World's First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions

A new clinical program is exploring whether ibogaine, a naturally occurring psychedelic, may help people with Parkinson’s disease, multiple sclerosis (MS), and traumatic brain injury (TBI). Led by Ambio Life Sciences, this is the first program of its kind in the world to offer ibogaine therapy for neurodegenerative conditions in a structured, supervised setting. 🧠 Why Ibogaine? Parkinson’s disease is caused by the loss of dopamine-producing brain cells. Some treatments aim to protect or restore these cells using a molecule called GDNF, but most methods are invasive. Ibogaine may help boost GDNF naturally, support neuroplasticity, and potentially aid brain repair—without surgery. Early animal studies suggest it could stimulate key brain regions involved in movement and mood. 💊 How the Program Works Patients start with a 4-day in-clinic treatment involving supervised ibogaine doses, followed by 6 months of microdosing at home. So far, 30 patients have enrolled. 💬 Patient Stories & Safety Measures Some participants, including NFL legend Brett Favre, have reported improvements in sleep, energy, mobility, and neuropathic pain. However, ibogaine can have serious side effects, especially on the heart. That’s why Ambio’s team carefully monitors heart function during treatment. Mild side effects may include nausea, tremors, or dream-like states. 🔬 The Science So Far A recent Stanford trial combining ibogaine and magnesium showed reduced disability in veterans with TBI, along with improvements in depression, anxiety, and PTSD—for at least a month after treatment. Ambio is now collecting long-term data from its Parkinson’s participants to learn more about ibogaine’s neuroprotective and restorative potential. 💙 A Step Toward Brain Healing While ibogaine is not a cure and won’t be right for everyone, this program is offering a new avenue of hope—especially for those who have long faced limited options. As Ambio’s team says: “Every participant is helping us learn what’s possible.”